Related Experiment Video
Updated: May 2, 2026
Multi-Scale Modification of Metallic Implants With Pore Gradients, Polyelectrolytes and Their Indirect Monitoring In vivo
Published on: July 1, 2013
Proteomic analysis of soft tissue tumor implants treated with a novel polybisphosphonate
Ayodele Alaiya1, Jonathan Fox, Steve Bobis
1Proteomics Unit, Stem Cell & Tissue Re-Engineering Program, King Faisal Specialist Hospital and Research Centre, (KFSH&RC) P.O. Box 3354, Riyadh, 11211 Saudi Arabia. AAlaiya@kfshrc.edu.sa.
Background:
Osteodex is a novel bi-functional macromolecular polybisphosphonate developed for treatment of bone metastases in prostate and breast cancer. High efficacy of osteodex has been demonstrated both in vitro and in vivo. The present study investigates whether osteodex is also efficacious on soft tissue tumor lesions.
Materials And Methods:
Twelve female nude mice were injected with MDA-MB-231 cells orthotopically. Osteodex was administered i.v. at 2.5 mg/kg, once per week for five weeks. Tumor volumes were measured during the treatment period, the animals were sacrificed, and samples collected for proteomic analysis.
Results:
The non-treated mice developed multiple tumors greater than 4 cm with pronounced ulceration, while the treated mice had tumors smaller than 1 cm, without ulceration. While general condition of treated mice was good, non-treated animals were in poor condition. Sixteen out of 300 identified proteins were differentially expressed, with statistically significant expression changes of more than two-fold differences between treated and non-treated groups. These proteins were identified using non-gel based nano-liquid chromatography coupled with a Synapt G2 instrument.
Conclusion:
We conclude that osteodex showed significant treatment efficacy on soft tissue tumor implants. The study provides a global view of changes in protein expression profiles following osteodex treatment. Some functions of the identified proteins might be used to explain the specific treatment efficacy of osteodex.
Insights
Osteodex effectively reduced soft tissue tumor growth in mice, demonstrating significant treatment efficacy. Proteomic analysis revealed key protein expression changes, offering insights into Osteodex
Area of Science:
- Oncology
- Pharmacology
- Proteomics
Background:
- Osteodex, a novel polybisphosphonate, is developed for bone metastases in prostate and breast cancer.
- Previous studies confirmed Osteodex's efficacy in vitro and in vivo for bone metastases.
- This study explored Osteodex's potential against soft tissue tumor lesions.
Purpose of the Study:
- To evaluate the efficacy of Osteodex in treating soft tissue tumors.
- To investigate the proteomic changes induced by Osteodex treatment in soft tissue tumors.
Main Methods:
- Female nude mice were orthotopically injected with MDA-MB-231 breast cancer cells.
- Osteodex was administered intravenously at 2.5 mg/kg weekly for five weeks.
- Tumor volumes were measured, and proteomic analysis was performed on collected samples.
Main Results:
- Osteodex treatment significantly inhibited tumor growth, with treated mice having tumors <1 cm compared to >4 cm in controls.
- Treated mice showed no ulceration and maintained good general condition, unlike untreated mice.
- Proteomic analysis identified 16 differentially expressed proteins ( >2-fold change) between groups using nano-LC-Synapt G2.
Conclusions:
- Osteodex demonstrates significant therapeutic efficacy against soft tissue tumor implants.
- The study provides a comprehensive proteomic profile of Osteodex treatment effects.
- Identified protein functions may elucidate Osteodex's mechanism of action in soft tissue tumors.
More Related Videos
07:53Peptides from Phage Display Library Modulate Gene Expression in Mesenchymal Cells and Potentiate Osteogenesis in Unicortical Bone Defects
Published on: December 10, 2010
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014